Navigation Links
Hypertension Diagnostics Announces Fiscal Year 2007 Results
Date:9/27/2007

ST. PAUL, Minn., Sept. 27 /PRNewswire-FirstCall/ -- Hypertension Diagnostics, Inc. (OTC Bulletin Board: HDII), today announced audited financial results for the fiscal year ended June 30, 2007.

Revenue for fiscal year 2007 totaled $1,878,840 compared to $1,789,546 in the prior year ended June 30, 2006, which represents a 5% increase. The Company incurred a net loss of $504,011 for fiscal year 2007, or $(.01) per share, compared with a net loss of $1,272,742 for fiscal year 2006, or $(.04) per share. Included in the net loss for fiscal year 2007 are total non-cash charges (expenses associated mainly with stock compensation, depreciation, stock options) of $290,989. The Company reported a cash balance on June 30, 2007 of $1,376,632.

Fourth quarter revenue of $438,481, for fiscal year 2007 compared to $295,536 for fiscal year 2006, represented a 48% increase. Revenue for the fourth quarter of fiscal year 2007 decreased by 6.5% compared with $469,151 for the third quarter of fiscal year 2007.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2006 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on Form 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

Hypertension Diagnostics, Inc.

Summary Financial Data

Statements of Operations

Three Months Ended Twelve Months Ended

June 30 June 30

2007 2006 2007 2006

Revenue:

Equipment sales $ 379,100 $ 209,500 $ 1,593,706 $ 1,352,486

Equipment rental 56,707 84,769 255,247 418,979

Service/contract

income 2,674 1,267 29,887 18,081

438,481 295,536 1,878,840 1,789,546

Cost of Sales 18,939 1,483 66,413 90,447

Gross Profit 419,542 294,053 1,812,427 1,699,099

Expenses:

Selling, general

and administrative 447,678 685,958 2,381,310 3,018,624

Total Expenses 447,678 685,958 2,381,310 3,018,624

Operating Loss (28,136) (391,905) (568,883) (1,319,525)

Other Income:

Interest income 14,558 16,338 56,773 46,783

Gain on sale of

property and

equipment - - 8,099 -

Total Other

Income 14,558 16,338 64,872 46,783

Net Loss $ (13,578) $ (375,567) $ (504,011) $(1,272,742)

Basic and Diluted

Net Loss

per Share $ (.00) $ (.01) $ (.01) $ (.04)

Weighted Average

Shares

Outstanding 39,620,262 39,714,469 39,793,320 35,219,474

Balance Sheet Data

June 30, 2007 June 30, 2006

Cash and cash

equivalents $ 1,376,632 $ 1,722,913

Total current assets 1,976,825 2,257,390

Total assets 2,020,385 2,345,949

Total current liabilities 582,124 489,081

Accumulated deficit (26,482,330) (25,978,319)

Total shareholders' equity 1,426,143 1,840,414

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.

Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Website: http://www.hdii.com


'/>"/>
SOURCE Hypertension Diagnostics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PRIMARY PULMONARY HYPERTENSION GENE DISCOVERED
2. New viewpoint on Hypertension
3. Hypertension drugs could lower Disability
4. Preventing white coat hypertension
5. New drug for hypertension
6. FDA Approves Remodulin for Pulmonary Hypertension
7. Risk of dementia reduced hypertension drugs
8. Glaucoma & Ocular Hypertension more likely in patients with refractive errors
9. Hypertension lowered by Bedtime Dosing
10. An hour of exercise a week cuts hypertension
11. Better Treatment For Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and ... Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when he ... He explains that the Bible details the current times so plainly that anyone ...
(Date:2/24/2017)... ... ... The Radiology Business Management Association will select the 2017 Quest ... Better Radiology Marketing Programs conference, held this year from March 5 to 7 ... given out in five categories. They are:, ,     Patient Marketing, a ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, the celebrated ... Giveaway, with the winning couple announced on Feb. 14, 2017, on Facebook. The ... local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring ...
(Date:2/23/2017)... ... 23, 2017 , ... The 89th Academy Awards will be celebrated this weekend, ... Policy Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” ... is the Center for American Progress (CAP), for its report, Lessons From State Performance ...
(Date:2/23/2017)... Chapel Hill, NC (PRWEB) , ... February 23, 2017 , ... ... the Platinum Sponsor for ACPA’s 74th Annual Meeting. KLS is a longtime supporter ... in 2017 as an exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... BRISBANE, Australia , Feb. 23, 2017  Directors from Pharma ... the two companies have joined forces, resulting in the founding of ... . Pharma To Market are pleased to announce their ... an office in Singapore . The company are ... Consulting as Co-Director of the Singapore based ...
(Date:2/24/2017)... 2017 Non-alcoholic steatohepataitis (NASH) Pipeline ... drugs being developed for the treatment of ... that are in various phases of development ... on novel pharmacologic drugs & regenerative medicines ... recombinant proteins and RNA-based therapeutics, but excludes ...
(Date:2/24/2017)... , Feb 24, 2017 Medivir ... proposal for a new Board of Directors that will ... 2016-2017 Nomination Committee comprises representatives of the company,s three ... of 2016 who have accepted a seat on the ... composition of the 2016-2017 Nomination Committee was as follows:  ...
Breaking Medicine Technology: